Letrozole

When ATH:
L02BG04

Pharmacological action.
Antitumor.

Application.

Common Breast Cancer, mainly in postmenopausal women, incl. with resistance to therapy antyэstrohenamy.

Contraindications.

Hypersensitivity, premenopausal period, expressed by the human kidney (Cl creatinine < 10 ml / min), pregnancy, lactation (stop).

Pregnancy and breast-feeding.

Category actions result in FDA - D. (There is evidence of the risk of adverse effects of drugs on the human fetus, obtained in research or practice, However, the potential benefits, associated with drugs in pregnant, may justify its use, in spite of the possible risk, if the drug is needed in life-threatening situations or severe disease, when safer agents should not be used or are ineffective.)

Side effects.

Headache, dizziness, generalized weakness, nausea, vomiting, change in appetite (often decrease), constipation, peripheral edema, tides, myalgia, ossalgia, weight change, thinning hair, gynecological bleeding, spotting from the vagina, skin rashes.

Dosing and Administration.

Inside, by 2,5 mg 1 once daily, long course (5-10 Years and more).

Precautions.

Before therapy is desirable to study the status of estrogenretseptornogo. The advisability of appointing patients without lymph node involvement is determined individually: take into account the degree of malignancy, tumor size, the presence of estrogen receptors, age. During the period of treatment is not recommended driving, etc.. activities, require greater attention and speed of reaction.